fda statement bpc-157 not approved for human use compounding Survey: Half of Peptide-Users Aren't Aware of Approval Status In 2023, the FDA deemed

2018;22(3):384-397.e6

It is currently in Phase 3 clinical trials

[DOI] [PMC free article] [PubMed] [Google Scholar] 285.Becker D.E., Reed K.L

2 for myself (bicep and shoulder injury), 1 for my mum (recurring shoulder injury that hasn't been fixed in 20 years) and 1 for dad who recently had reconstructive shoulder surgery, but is still having issues

Beyond simply concentrating on B12 deficiency, it becomes paramount to address the matter of declined sensitivity to B12

Phase 2b doses were 0.25 to 1.0 mg daily, which at a 2.5 mg/ml concentration means 0.1 to 0.4 ml per injection, conveniently measurable on a 1 ml insulin syringe